EE200200044A - Antisenss-oligonukleotiid või selle derivaat, selle valmistamismeetod ja kasutamine, meetod eg5 ekspressiooni inhibeerimiseks ning farmatseutiline kompositsioon ja selle valmistamismeetod - Google Patents

Antisenss-oligonukleotiid või selle derivaat, selle valmistamismeetod ja kasutamine, meetod eg5 ekspressiooni inhibeerimiseks ning farmatseutiline kompositsioon ja selle valmistamismeetod

Info

Publication number
EE200200044A
EE200200044A EEP200200044A EEP200200044A EE200200044A EE 200200044 A EE200200044 A EE 200200044A EE P200200044 A EEP200200044 A EE P200200044A EE P200200044 A EEP200200044 A EE P200200044A EE 200200044 A EE200200044 A EE 200200044A
Authority
EE
Estonia
Prior art keywords
preparation
inhibiting
derivative
expression
pharmaceutical composition
Prior art date
Application number
EEP200200044A
Other languages
English (en)
Estonian (et)
Inventor
Uhlmann Eugen
Greiner Beate
Unger Eberhard
Gothe Gislinde
Schwerdel Marc
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of EE200200044A publication Critical patent/EE200200044A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EEP200200044A 1999-07-28 2000-07-21 Antisenss-oligonukleotiid või selle derivaat, selle valmistamismeetod ja kasutamine, meetod eg5 ekspressiooni inhibeerimiseks ning farmatseutiline kompositsioon ja selle valmistamismeetod EE200200044A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19935303A DE19935303A1 (de) 1999-07-28 1999-07-28 Oligonukleotide zur Inhibierung der Expression von humanem eg5
PCT/EP2000/007345 WO2001007602A2 (de) 1999-07-28 2000-07-21 Oligonukleotide zur inhibierung der expression von humanem eg5

Publications (1)

Publication Number Publication Date
EE200200044A true EE200200044A (et) 2003-06-16

Family

ID=7916259

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200044A EE200200044A (et) 1999-07-28 2000-07-21 Antisenss-oligonukleotiid või selle derivaat, selle valmistamismeetod ja kasutamine, meetod eg5 ekspressiooni inhibeerimiseks ning farmatseutiline kompositsioon ja selle valmistamismeetod

Country Status (26)

Country Link
US (1) US6472521B1 (xx)
EP (1) EP1204742A2 (xx)
JP (1) JP2003505080A (xx)
KR (1) KR20020033744A (xx)
CN (1) CN1165617C (xx)
AR (1) AR024953A1 (xx)
AU (1) AU6568200A (xx)
BR (1) BR0013180A (xx)
CA (1) CA2380192A1 (xx)
CZ (1) CZ2002324A3 (xx)
DE (1) DE19935303A1 (xx)
EE (1) EE200200044A (xx)
HK (1) HK1048337B (xx)
HR (1) HRP20020075A2 (xx)
HU (1) HUP0202794A3 (xx)
IL (1) IL147541A0 (xx)
MX (1) MXPA02000817A (xx)
NO (1) NO20020365L (xx)
NZ (1) NZ516839A (xx)
PL (1) PL353733A1 (xx)
RU (1) RU2249458C2 (xx)
SK (1) SK1162002A3 (xx)
TR (1) TR200200201T2 (xx)
WO (1) WO2001007602A2 (xx)
YU (1) YU91901A (xx)
ZA (1) ZA200200655B (xx)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617115B1 (en) * 1999-10-27 2003-09-09 Cytokinetics, Inc. Methods of screening for modulators of cell proliferation
US6440686B1 (en) 2000-06-15 2002-08-27 Cytokinetics, Inc. Methods for screening and therapeutic applications of kinesin modulators
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US6809102B2 (en) 2001-03-29 2004-10-26 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US20040009156A1 (en) * 2001-10-12 2004-01-15 Christoph Reinhard Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer
US7199107B2 (en) 2002-05-23 2007-04-03 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
US7163927B2 (en) * 2002-05-23 2007-01-16 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
JP2006521794A (ja) * 2003-02-14 2006-09-28 スミスクライン・ビーチャム・コーポレイション Ｋｓｐ発現と相関関係にある示差発現核酸
US7662581B1 (en) 2003-12-18 2010-02-16 Novartis Vaccines And Diagnostics, Inc. Eg5 co-crystals
WO2005090603A2 (en) * 2004-03-23 2005-09-29 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancer
US7700567B2 (en) * 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
WO2007115168A2 (en) * 2006-03-31 2007-10-11 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of eg5 gene
RU2568579C2 (ru) * 2006-05-26 2015-11-20 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" Введение противосвертывающей системы reg1
RU2464030C2 (ru) * 2006-05-26 2012-10-20 Регадо Байосайенсиз, Инк. Введение противосвертывающей системы reg1
AU2008326187B2 (en) * 2007-11-06 2014-12-04 Adiutide Pharmaceuticals Gmbh Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
DE102010007562A1 (de) 2010-02-10 2011-08-11 sterna biologicals GmbH & Co KG, 35043 Dermatologische, pharmazeutische Zusammensetzung geeignet für Oligonukleotide
CN103945902B (zh) 2011-08-30 2018-07-20 阿斯泰克斯制药公司 地西他滨衍生物制剂
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
WO2014179620A1 (en) 2013-05-01 2014-11-06 Isis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
EP3715457A3 (en) * 2013-08-28 2020-12-16 Ionis Pharmaceuticals, Inc. Modulation of prekallikrein (pkk) expression
WO2015054676A2 (en) * 2013-10-11 2015-04-16 Isis Pharmaceuticals, Inc. Compositions for modulating c9orf72 expression
ES2941742T3 (es) * 2014-05-01 2023-05-25 Ionis Pharmaceuticals Inc Composiciones y procedimientos para modular la expresión del factor B del complemento
CN108024535A (zh) 2015-07-02 2018-05-11 大塚制药株式会社 冻干药物组合物
RU2020108580A (ru) 2017-08-03 2021-09-03 Оцука Фармасьютикал Ко., Лтд. Лекарственное соединение и способы его очистки

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0171066A3 (de) 1984-08-09 1989-02-01 Siemens Aktiengesellschaft Verfahren und Schaltungsanordnung zum Adressieren von Signalabgabe-/Signalaufnahmeeinrichtungen von einer zentralen Verarbeitungseinrichtung her
ES2099718T3 (es) 1990-07-02 1997-06-01 Hoechst Ag Analogos de oligonucleotidos con uniones internucleotidicas de 3'-3' o 5'-5' terminales.
US6033909A (en) 1992-01-22 2000-03-07 Hoechst Aktiengesellschaft Oligonucleotide analogs, their preparation and use
FI115214B (fi) 1992-01-22 2005-03-31 Hoechst Ag Menetelmä oligonukleotidianalogien valmistamiseksi ja niiden käyttö
ATE151773T1 (de) 1992-09-24 1997-05-15 Hoechst Ag Oligoribonucleotid- und ribozym-analoga mit terminalen 3'-3'-bzw.5'-5'-verknüpfungen
GB9311113D0 (en) * 1993-05-28 1993-07-14 Medical Res Council Probes
DE4321946A1 (de) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
DE4338704A1 (de) 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
DE4408528A1 (de) 1994-03-14 1995-09-28 Hoechst Ag Peptid-Oligonucleotid-Derivate, deren Herstellung und Verwendung
DE4415370A1 (de) 1994-05-02 1995-11-09 Hoechst Ag Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
DE4438918A1 (de) 1994-11-04 1996-05-09 Hoechst Ag Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
DE19502912A1 (de) 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
DK0739898T3 (da) 1995-03-13 2001-12-10 Aventis Pharma Gmbh Phosphononmoneosternukleinsyrer, fremgangsmåde til fremstilling deraf og anvendelse deraf
US6309821B1 (en) * 1996-05-16 2001-10-30 Incyte Genomics, Inc. DNA encoding a PAC10 human homolog
AU8656098A (en) * 1997-07-23 1999-02-16 Brigham And Women's Hospital Lens epithelial cell derived growth factor
WO1999038972A2 (en) * 1998-01-28 1999-08-05 Chiron Corporation Human genes and gene expression products ii

Also Published As

Publication number Publication date
HRP20020075A2 (en) 2005-10-31
WO2001007602A3 (de) 2001-05-17
HUP0202794A3 (en) 2006-03-28
JP2003505080A (ja) 2003-02-12
US6472521B1 (en) 2002-10-29
KR20020033744A (ko) 2002-05-07
CN1367828A (zh) 2002-09-04
WO2001007602A2 (de) 2001-02-01
CZ2002324A3 (cs) 2002-05-15
EP1204742A2 (de) 2002-05-15
AU6568200A (en) 2001-02-13
TR200200201T2 (tr) 2002-05-21
RU2249458C2 (ru) 2005-04-10
HK1048337B (zh) 2005-02-25
NO20020365L (no) 2002-03-25
HK1048337A1 (en) 2003-03-28
NO20020365D0 (no) 2002-01-23
YU91901A (sh) 2003-02-28
CA2380192A1 (en) 2001-02-01
AR024953A1 (es) 2002-10-30
IL147541A0 (en) 2002-08-14
SK1162002A3 (en) 2002-06-04
ZA200200655B (en) 2003-09-23
NZ516839A (en) 2004-04-30
HUP0202794A2 (en) 2003-03-28
DE19935303A1 (de) 2001-02-08
CN1165617C (zh) 2004-09-08
BR0013180A (pt) 2002-04-09
PL353733A1 (en) 2003-12-01
MXPA02000817A (es) 2002-07-30

Similar Documents

Publication Publication Date Title
EE200200044A (et) Antisenss-oligonukleotiid või selle derivaat, selle valmistamismeetod ja kasutamine, meetod eg5 ekspressiooni inhibeerimiseks ning farmatseutiline kompositsioon ja selle valmistamismeetod
HUP0203453A3 (en) Quinazoline derivatives as vegf inhibitors, process for their preparation, pharmaceutical compositions containing them and their use
EE200100684A (et) Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE05086B1 (et) Primidiini derivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod, kombinatsioon ning saadus
EE200100431A (et) 16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine
HUP0203548A3 (en) New spirooxindole derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0104204A3 (en) Pyrazolopyridine derivatives as cox-2 inhibitors, process for their preparation and pharmaceutical compositions thereof
HK1042891A1 (en) Benzene derivatives, preparation method and pharmaceutical compositions containing same
EE04915B1 (et) Kinuklidiinderivaadid, nende valmistamismeetod, vahehendid, farmatseutiline kompositsioon ja nende kasutamine
EE200000596A (et) Tienüülasolüülalkoksüetaanamiinderivaadid, nende ja nende soolade valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja kasutamine ning vaheühend ja selle valmistamismeetod
EE05081B1 (et) Farmatseutilised kompositsioonid, mis sisaldavad 3-aminoasetidiini derivaate, 3-aminoasetidiini derivaadid ja nende valmistamise meetodid
HUP0300618A3 (en) Adamantana derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP0301315A3 (en) Benzothiazole derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP0202075A3 (en) Substituted 2-dialkylaminoalkylbiphenyl derivatives, process for their preparation, pharmaceutical compositions containing them and their use
EE200200655A (et) 5-kloro-3-(4-metaansulfonüülfenüül)-6'-metüül[2,3']bipüridinüüli polümorfne vorm, selle valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
EE200100653A (et) Indolüülpiperidiinühendid, nende valmistamismeetod, kompositsioon ja nende kasutamine
HUP0204354A3 (en) Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same and their use
EE200000651A (et) Asoolid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
HUP0201315A3 (en) 4-phenyl-pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them
EE04902B1 (et) Mikrograanul, selle valmistamismeetod ja farmatseutiline preparaat
HUP0202988A3 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one derivatives and their use as lipase inhibitors, process for their preparation and pharmaceutical compositions containing them
EE200100711A (et) Naftüridiini derivaadid, nende valmistamismeetod ning neid sisaldav farmatseutiline kompositsioon
EE200000569A (et) PDE IV inhibeerivad püridiini derivaadid, nende valmistamismeetod ja kasutamine ning farmatseutiline kompositsioon ja selle valmistamismeetod
HUP0203859A3 (en) Aminomethyl-phenyl-cyclohexanone derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0201797A3 (en) 3-amino-2-benzyl-1-phenyl-propane derivatives, process for their preparation, pharmaceutical compositions containing them and their use